Knowing stock market today at a glance

Akebia Therapeutics Soars 15.85% on Earnings Surprise

Mover TrackerThursday, May 8, 2025 8:27 am ET

1min read

Akebia Therapeutics' stock surged 15.85% in pre-market trading on May 8, 2025, driven by strong first-quarter earnings and revenue surprises.

Akebia Therapeutics reported a 200% earnings surprise and a 26.83% revenue surprise for the quarter ended March 2025. The company's performance exceeded analyst expectations, contributing to the significant pre-market rally.

The consensus earnings per share (EPS) estimate for the first quarter of 2025 was -$0.04, while the consensus revenue estimate was $44.53 million, representing a 36.6% year-over-year increase. Akebia Therapeutics has a history of beating EPS estimates, which further bolstered investor confidence.

Looking ahead, the company's fiscal year 2025 and 2026 estimate trends show a mix of positive and negative projections, indicating a range of expectations among analysts. However, the strong Q1 performance suggests that Akebia Therapeutics is on track to meet or exceed these estimates.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.